Autonomic Nervous System Drugs Practice Questions

Q: The drug used in an ameliorative test for myasthenia gravis is

Edrophonium. ***Edrophonium*** - **Edrophonium** is a **short-acting acetylcholinesterase inhibitor** used in the **Tensilon test** for diagnosing myasthenia gravis. - Its rapid onset and brief duration of action (5-10 minutes) allow for quick assessment of symptomatic improvement in patients with the disease. *Physostigmine* - **Physostigmine** is an **acetylcholinesterase inhibitor** that can cross the **blood-brain barrier**, making it useful for treating anticholinergic toxicity. - It has a longer duration of action than edrophonium and is not typically used for the acute diagnostic test of myasthenia gravis. *Tacrine* - **Tacrine** is an **acetylcholinesterase inhibitor** primarily used in the management of **Alzheimer's disease** to improve cognitive function. - It is not used for the diagnosis or short-term ameliorative testing of myasthenia gravis. *Pyridostigmine* - **Pyridostigmine** is an **intermediate-acting acetylcholinesterase inhibitor** used for the chronic symptomatic treatment of myasthenia gravis. - While it improves muscle strength, its longer duration of action (3-6 hours) makes it unsuitable for the rapid diagnostic "Tensilon test."

Q: Which of the following is not a carbamate?

Edrophonium. ***Edrophonium*** - **Edrophonium** is a **short-acting acetylcholinesterase inhibitor** that is not a carbamate. - Its action is very rapid in onset and brief in duration, unlike carbamates which have a longer duration of action due to a more stable bond with acetylcholinesterase. *Physostigmine* - **Physostigmine** is a **tertiary amine carbamate** that can cross the blood-brain barrier. - It works by reversibly inhibiting acetylcholinesterase, leading to increased acetylcholine levels, and has a duration of action of 2-4 hours. *Neostigmine* - **Neostigmine** is a **quaternary ammonium carbamate** that does not cross the blood-brain barrier effectively. - It is used to treat myasthenia gravis and reverse the effects of non-depolarizing neuromuscular blockers, with a duration of action of 2-4 hours. *Pyridostigmine* - **Pyridostigmine** is also a **quaternary ammonium carbamate** and is commonly used for the long-term treatment of myasthenia gravis. - Like neostigmine, it does not cross the blood-brain barrier and has a longer duration of action (3-6 hours) compared to physostigmine.

Q: Sympathomimetic drugs are useful in the therapy of all of the following conditions except:

Hypertension. ***Hypertension*** - Sympathomimetic drugs **mimic the effects of the sympathetic nervous system**, leading to **increased heart rate, contractility, and vasoconstriction**, which would worsen hypertension. - Their primary action is to activate **adrenergic receptors**, thereby elevating blood pressure rather than lowering it. - Sympathomimetics are **contraindicated in hypertensive patients** as they would exacerbate the elevated blood pressure. *Hypotension* - Sympathomimetic drugs are highly effective in treating hypotension, particularly in conditions like **shock**. - They cause **vasoconstriction (alpha-1 agonism)** and/or **increased cardiac output (beta-1 agonism)**, thereby raising blood pressure. - Agents like **norepinephrine, phenylephrine, and dopamine** are commonly used in critical care settings. *Acute decompensated heart failure* - Sympathomimetics with **beta-1 adrenergic agonist** effects (e.g., **dobutamine**) can improve cardiac contractility and output in acute decompensated heart failure. - These agents help to **increase myocardial performance** in situations where the heart is failing to pump adequately. - They provide temporary hemodynamic support in acute settings. *Nasal congestion* - **Alpha-1 adrenergic agonists** (e.g., **phenylephrine, pseudoephedrine**) are widely used as nasal decongestants. - They cause **vasoconstriction of nasal blood vessels**, reducing mucosal edema and improving airflow. - Available as both topical nasal sprays and oral formulations for symptomatic relief of nasal congestion.

Q: Metyrosine is used in the treatment of?

Pheochromocytoma. ***Pheochromocytoma*** - **Metyrosine** inhibits **tyrosine hydroxylase**, the rate-limiting enzyme in **catecholamine synthesis**, thus reducing the production of **epinephrine** and **norepinephrine**. - Its primary use is in the preoperative management of **pheochromocytoma** to prevent **hypertensive crises** during surgery, and in patients with inoperable or metastatic disease to control symptoms. *Acromegaly* - **Acromegaly** is characterized by excessive **growth hormone** production. - Treatment typically involves **somatostatin analogs**, **GH receptor antagonists**, or surgery, not metyrosine. *Cushing syndrome* - **Cushing syndrome** results from prolonged exposure to **high cortisol levels**. - Management focuses on reducing **cortisol** production or surgical removal of the underlying cause, not primarily involving metyrosine. *Addison's disease* - **Addison's disease** is caused by **adrenal insufficiency** leading to deficient **cortisol** and **aldosterone**. - Treatment involves **hormone replacement therapy** with glucocorticoids and mineralocorticoids.

Q: Which of the following is the longest acting ocular beta blocker?

Levobunolol. ***Levobunolol*** - Levobunolol is the **longest-acting ocular beta-blocker**, with a duration of action of approximately **24 hours**, allowing for **once-daily dosing** in many patients. - It is a **non-selective beta-blocker** (blocks both beta-1 and beta-2 receptors) that effectively reduces intraocular pressure in glaucoma management. - Its extended duration makes it particularly convenient for patient compliance compared to other ocular beta-blockers. *Betaxolol* - Betaxolol is a **beta-1 selective blocker** with a duration of action of approximately **12 hours**, typically requiring **twice-daily dosing**. - Its selectivity may offer a better systemic safety profile regarding respiratory side effects compared to non-selective agents. - While effective, it does not have the longest duration of action among ocular beta-blockers. *Carteolol* - Carteolol is a **non-selective beta-blocker** with **intrinsic sympathomimetic activity (ISA)**. - It has a duration of action of approximately **12 hours** and usually requires **twice-daily administration**. - The ISA property may theoretically reduce some systemic side effects but does not extend its duration of action. *Timolol* - Timolol is a **non-selective beta-blocker** widely used in ophthalmology with a duration of action of approximately **12 hours**. - It typically requires **twice-daily dosing** and is highly effective for reducing intraocular pressure. - Its non-selective nature can lead to systemic side effects like **bronchospasm** in susceptible individuals.

Q: Which of the following drugs possesses the maximum action on nicotinic receptors?

Carbachol. ***Carbachol*** - **Carbachol** is a stable choline ester with prominent **nicotinic agonist activity**, making it the cholinergic agent with the greatest action on nicotinic receptors among the options listed. - Its **dual muscarinic and nicotinic effects** are due to its chemical structure, making it less selective than some other cholinergic agents. *Bethanechol* - **Bethanechol** is a choline ester that primarily acts on **muscarinic receptors** and has very little to no nicotinic activity. - It is used clinically for its muscarinic effects, such as increasing **bladder motility** or treating **gastric atony**. *Pilocarpine* - **Pilocarpine** is an alkaloid with strong, selective **muscarinic agonist activity**, making it particularly useful for conditions like **glaucoma** (by increasing aqueous humor outflow) and **xerostomia**. - It exhibits negligible activity at **nicotinic receptors**. *Methacholine* - **Methacholine** is a choline ester that primarily stimulates **muscarinic receptors**, though it has more nicotinic action than bethanechol. - It is known for its use in **bronchial challenge tests** to diagnose **asthma** due to its role in causing bronchoconstriction via muscarinic stimulation.

Q: What distinguishes betaxolol from timolol in terms of its pharmacological properties?

Is a selective β1 blocker. ***Is a selective β1 blocker*** - **Betaxolol** is a **cardioselective β1-adrenergic antagonist**, meaning it primarily blocks β1 receptors in the heart and **juxtaglomerular apparatus**. - **Timolol**, in contrast, is a **non-selective β-blocker**, affecting both β1 and β2 receptors, which can lead to more systemic side effects. *Has superior efficacy in treating glaucoma* - Both betaxolol and timolol are effective in **reducing intraocular pressure (IOP)** by decreasing aqueous humor production, with **timolol generally showing equivalent or slightly greater efficacy**. - **Timolol's non-selective action** may sometimes lead to a marginal advantage in IOP reduction, though **betaxolol is preferred** in some patients due to its selectivity. *Causes fewer ocular side effects than timolol* - While betaxolol is generally associated with **fewer systemic side effects** due to its cardioselectivity, it can actually cause **more ocular stinging and irritation** compared to timolol. - Some studies suggest a comparable incidence of other ocular side effects like **dry eye or blurred vision** between the two drugs. *Has a shorter duration of action than timolol* - Both betaxolol and timolol are applied **topically once or twice daily** to manage glaucoma, indicating a **similar long duration of action** suitable for sustained IOP control. - There is no clinical evidence to suggest that betaxolol has a significantly shorter duration of action that would warrant more frequent dosing compared to timolol.

Q: Which of the following statements about d-tubocurarine is true?

Is a non-depolarizing neuromuscular blocking agent.. ***Is a non-depolarizing neuromuscular blocking agent*** - D-tubocurarine is a **classic non-depolarizing neuromuscular blocker (NDNMB)**, acting as a competitive antagonist at nicotinic receptors - This is the **fundamental classification** that defines its mechanism and distinguishes it from depolarizing agents like succinylcholine - Non-depolarizing agents can be reversed with anticholinesterases (neostigmine, pyridostigmine) *Causes histamine release leading to hypotension* - While this statement is **medically accurate**, d-tubocurarine does cause significant histamine release - This side effect leads to hypotension, bronchospasm, and tachycardia - However, this is a **side effect** rather than the primary defining characteristic of the drug *Blocks nicotinic receptors at the neuromuscular junction* - This statement is also **factually correct** - d-tubocurarine blocks nicotinic ACh receptors at NMJ - This is the **mechanism of action** of all non-depolarizing blockers - However, the classification as "non-depolarizing" is the broader, more fundamental concept tested *Has intermediate duration of action (30-60 minutes)* - This is **INCORRECT** - d-tubocurarine is classified as a **long-acting** neuromuscular blocker - Duration of action: **90-120+ minutes**, not intermediate - Intermediate-acting agents include atracurium, vecuronium, and rocuronium (30-60 min)

Q: Which short-acting anticholinesterase drug is primarily used for the diagnosis of myasthenia gravis?

Edrophonium. ***Edrophonium*** - This **short-acting anticholinesterase** reversibly inhibits acetylcholinesterase, leading to a temporary increase in acetylcholine at the neuromuscular junction. - The **Tensilon test** uses edrophonium to rapidly assess for improved muscle strength in patients suspected of having myasthenia gravis. *Demecarium* - This is a **long-acting cholinesterase inhibitor** and is not typically used for the fast diagnostic test of myasthenia gravis due to its extended duration of action. - It was historically used in the treatment of glaucoma, not for acute diagnostic purposes in neuromuscular disorders. *Dyflos* - Also known as **diisopropyl fluorophosphate (DFP)**, Dyflos is an **irreversible organophosphorus cholinesterase inhibitor**. - Its long-lasting and toxic effects make it unsuitable and dangerous for diagnostic testing of myasthenia gravis. *Echothiophate* - This is another **long-acting, irreversible cholinesterase inhibitor** primarily used in the treatment of glaucoma. - Its irreversible nature and prolonged effects are not suitable for the quick, reversible diagnostic test needed for myasthenia gravis.

Q: What do organophosphates inhibit in the human body?

The esteratic site of acetylcholinesterase (AchE). ***The esteratic site of acetylcholinesterase (AchE)*** - Organophosphates are **irreversible inhibitors** that bind covalently to the **esteratic site** (serine hydroxyl group) of acetylcholinesterase. - This binding prevents the enzyme from hydrolyzing **acetylcholine**, leading to its accumulation in the synaptic cleft. - This covalent phosphorylation is the hallmark of organophosphate poisoning. *The anionic site of acetylcholinesterase (AchE)* - The **anionic site** of acetylcholinesterase binds to the **quaternary ammonium group** of acetylcholine, facilitating its orientation for hydrolysis at the esteratic site. - While important for enzyme function, organophosphates do not primarily act by inhibiting this site. - Reversible cholinesterase inhibitors (like edrophonium) interact with both sites but do not form covalent bonds. *Acetylcholine (Ach)* - Organophosphates do not directly inhibit **acetylcholine** itself. - Instead, they inhibit the **enzyme that breaks down acetylcholine** (acetylcholinesterase). - The accumulation of acetylcholine is a **consequence** of enzyme inhibition, not the primary target of organophosphate action. *None of the options* - This option is incorrect because the first option accurately describes the specific site of organophosphate inhibition on acetylcholinesterase.

Question 1

The drug used in an ameliorative test for myasthenia gravis is

Accepted Answer

Edrophonium

Answer

Physostigmine

Answer

Tacrine

Answer

Pyridostigmine

Question 2

Which of the following is not a carbamate?

Accepted Answer

Edrophonium

Answer

Physostigmine

Answer

Neostigmine

Answer

Pyridostigmine

Question 3

Sympathomimetic drugs are useful in the therapy of all of the following conditions except:

Accepted Answer

Hypertension

Answer

Hypotension

Answer

Acute decompensated heart failure

Answer

Nasal congestion

Question 4

Metyrosine is used in the treatment of?

Accepted Answer

Pheochromocytoma

Answer

Cushing syndrome

Answer

Addison's disease

Answer

Acromegaly

Question 5

Which of the following is the longest acting ocular beta blocker?

Accepted Answer

Levobunolol

Answer

Carteolol

Answer

Betaxolol

Answer

Timolol

Question 6

Which of the following drugs possesses the maximum action on nicotinic receptors?

Accepted Answer

Carbachol

Answer

Bethanechol

Answer

Pilocarpine

Answer

Methacholine

Question 7

What distinguishes betaxolol from timolol in terms of its pharmacological properties?

Accepted Answer

Is a selective β1 blocker

Answer

Has superior efficacy in treating glaucoma

Answer

Causes fewer ocular side effects than timolol

Answer

Has a shorter duration of action than timolol

Question 8

Which of the following statements about d-tubocurarine is true?

Accepted Answer

Is a non-depolarizing neuromuscular blocking agent.

Answer

Causes histamine release leading to hypotension.

Answer

Blocks nicotinic receptors at the neuromuscular junction.

Answer

Has intermediate duration of action (30-60 minutes).

Question 9

Which short-acting anticholinesterase drug is primarily used for the diagnosis of myasthenia gravis?

Accepted Answer

Edrophonium

Answer

Demecarium

Answer

Dyflos

Answer

Echothiophate

Question 10

What do organophosphates inhibit in the human body?

Accepted Answer

The esteratic site of acetylcholinesterase (AchE)

Answer

The anionic site of acetylcholinesterase (AchE)

Answer

Acetylcholine (Ach)

Answer

None of the options

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?